Overexpression of discoidin domain receptor 1 (DDR1) is known to enhance the malignancy of breast cancer considerably. This study reports the identification of a potent DDR1 inhibitor, nilotinib, for the treatment of breast cancer. MTT assay was used to evaluate the inhibitory activity of nilotinib and meantime we used flow cytometry to evaluate the pro-apoptotic activity of nilotinib in MCF-7 and MDA-MB-231 cells.
View Article and Find Full Text PDF